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Abstract 
   An inhaler adapter has been designed for the characterisation of the aerosol clouds 
generated by medical aerosol generators such as nebulisers, dry powder inhalers (dpi’s) and 
metered dose inhalers (mdi’s) with laser diffraction technology. The adapter has a pre-
separator for separation of large particles (i.e. carrier crystals) before the aerosol is exposed to 
the laser beam. The adapter also has a fine particle collector for measuring the emitted mass 
fraction of fines by chemical detection methods after laser diffraction sizing. The closed 
system enables flow control through the aerosol generators. Additionally, all test conditions 
are automatically recorded. This includes temperature and relative humidity of the air. 
Counter flows minimize particle deposition onto the two windows for the laser beam, which 
make successive measurements without cleaning of these windows possible. The adapter has 
successfully been tested for nebulisers, mdi’s and dry powder inhalers. In a comparative study 
with 10 frequently applied nebuliser-compressor combinations it was found that the 
combinations differ considerably in droplet size (distribution) of the aerosol cloud for the 
same 10% aqueous tobramycin solution (volume median diameters ranging from 1.25 to 3.25 
µm) when they are used under the conditions recommended by the manufacturers. The droplet 
size distribution generated by the Sidestream with a PortaNeb compressor is very constant 
during nebulisation until dry running of the device. Comparative testing of dpi’s containing 
spherical pellet type of formulations for the drug (e.g. the Astra Turbuhaler) with the adapter 
is fast and simple. But also formulations containing larger carrier particles could successfully 
be measured. De-agglomeration efficiency of a test inhaler with carrier retention (acting as a 
pre-separator) could be measured quite accurately both for a colistin sulfate formulation with 
16.7% (sweeper) lactose in a size fraction of 106-150 µm, and for a budesonide formulation 
with a carrier mixture of Pharmatose 325 and 150 M. Therefore, it is concluded that, with this 
special adapter, laser diffraction may be a valuable tool for comparative inhaler evaluation, 
device development, powder formulation and quality control. Compared to cascade impactor 
analysis, laser diffraction is much faster. In addition to that, more detailed and also different 
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1. Introduction 
 Multi stage liquid impingers (MSLI’s) and cascade impactors are widely used for 
particle size measurement in the aerosol cloud from medical aerosol generators and many 
different types of devices are available. The principle of classification by inertial separation is 
well described (e.g. Ranz and Wong, 1952; Hinds, 1982; John, 1999) and the technique is 
popular because the emitted dose is fractionated into aerodynamic size classes that are 
relevant to the drug deposition in the respiratory tract. Because these fractions are analysed by 
chemical detection methods, drug can be measured in the presence of excipient. Recently, a 
series of developments has been presented to increase the accuracy, applicability and 
versatility of cascade impaction. A new apparatus has been developed specifically for 
pharmaceutical applications. It is referred to as the Next Generation Impactor (NGI: Marple, 
2000). In order to improve the performance of this device, a special high-capacity pre-
separator has been designed (Roberts et al., 2000). Robot assisted inhaler handling during 
cascade impactor analysis (cia) and automated data processing have been introduced to 
increase the speed and accuracy of testing (Copley, 2000; Smith, 2000). To study the effect of 
simulated inhalation profiles on the performance of aerosol delivery systems, different set-ups 
have been presented to maintain a constant air flow through the cascade impactor (Burnell et 
al., 1998; Miller et al., 2000; Finlay and Gehmlich, 2000). In order to extend the sizing range 
of impactors, e.g. for the characterisation of agglomerated drug particles or drug particles 
attached to carrier crystals in the emitted aerosol cloud from dry powder inhalers (dpi’s), 
combinations of impactors and cascade sieves have been proposed (Prime et al., 2000). For 
many other shortcomings and limitations of cascade impaction (summarised in Table 3.1), 
adequate solutions have not (yet) been found however. Particularly the time necessary to 
complete an analysis, even with the help of robot assisted inhaler handling and automatic data 
processing, limits device and formulation development. 
 
Table 3.1. Review of some specific advantages and limitations of cascade impaction (cia). 
Advantages 9 Quantitative and qualitative drug analysis with chemical detection methods 
9 Mass fractions are classified upon ‘aerodynamic diameters’ 
9 Widespread acceptance and use 
9 Data are currently accepted by regulatory authorities 
Limitations 9 Classification is into a small number of size classes 
9 Cascade impactors can not be operated under variable flow conditions: flow 
curve simulation is not possible 
9 Cut-off diameters vary with (fixed) flow rate through the impactor 
9 High resistance limits the adjustable range of flow rates 
9 The effect of flow increase rate on dpi performance can not be studied 
9 Fine particle collection by adhesion and electrostatic charge may occur 
9 Cascade impaction lacks precision 
9 Cascade impaction is slow and laborious 
 
 
 Laser diffraction analysis (lda) has the potential to solve some major disadvantages of 
cia. It also has some specific features (de Boer et al., 2002) that may be particularly 
interesting for inhaler characterisation. For instance (Table 3.2), lda offers a much higher 
number of size classes within the relevant fine particle fraction than can be obtained from 
cascade impactor analysis. Therefore, calculation of comparable fractions is much easier, 
faster and with higher accuracy. The sizing principle has no collection plates that can dry up 
or get overloaded with particles during longer measuring periods, thereby increasing the 
occurrence of bounce and blow off. These practical advantages are the reason why lda is 
already frequently applied for testing of nebulisers which requires long measuring times 
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(Clark, 1995; McCallion et al., 1995, 1996a/b; Bridges and Taylor, 1998). This is in spite of 
the fact that standard laser diffraction equipment does not enable to control the inspiratory 
flow curve through the inhaler. This limitation seems to exclude testing of breath controlled 
devices with this technique, unless an air flow is directed through the device by compression 
instead of suction (Everard et al., 1997). Lda neither exclusively yields the size distribution of 
the drug when excipient particles are present in the aerosol. Nor are aerodynamic diameters 
obtained with laser diffraction. Moreover, the mass fraction of the dose that is emitted as fine 
particles can not be measured with standard apparatus. It requires special techniques and 
additional equipment to find proper solutions for these practical (and operational) 
shortcomings, as will be described in this chapter. For instance, the application of lda for dpi 
development should be based on reference measurements. The laser diffraction size 
distribution of the primary drug particles (of which the aerodynamic size distribution may be 
known from other measuring principles) obtained with RODOS dispersion is the reference 
during powder formulation and device development. Also, a different way of data 
interpretation has to be developed; e.g. by explaining the results in terms of powder de-
agglomeration efficiencies. This confines lda not only to a very fast and reliable technique for 
nebulisers and metered dose inhalers (mdi’s) but stretches its application to dpi development 
as well.  
 
Table 3.2. Review of some specific advantages and limitations of laser diffraction (lda). 
Advantages 9 Rapid data generation and processing 
9 Highly accessible to automation 
9 High accuracy and reproducibility 
9 Size measurement is independent of the flow rate: simulation of 
inspiratory flow curves is possible 
9 A high number of size classes within the size range relevant to lung 
deposition is obtained 
9 Time sliced measurements enable examination of changes in the size 
distribution of the aerosol as function of the inhalation time 
Limitations 9 Standard laser diffraction does not exclusively yield the size distribution 
of the drug (in the presence of excipient particles) 
9 Geometric, instead of aerodynamic particle diameters are measured 
 
 
 In this chapter, the design and development of a modular inhaler adapter for laser 
diffraction characterisation of different types of inhalation devices is presented and discussed. 
The aim is to show that the adapter facilitates fast and accurate (comparative) evaluation of 
nebulisers (and mdi’s). But also the performance of breath operated dry powder inhalers can 
be studied quite conveniently. This includes devices which contain formulations with larger 
carrier particles. It will be shown that reliable size distributions of the drug in the aerosol 
cloud can be obtained when effective pre-separators are used to remove large excipient (e.g. 
carrier) particles and reference measurements with pure excipient are made that serve as a 




2. Design of a modular inhaler adapter and its features 
 Recommended additional means to obtain a practical solution for some of the major 
restrictions of lda for inhaler testing are: 
9 A closed housing to which the inhaler is connected and through which the aerosol is 
conducted at a controlled inspiratory flow rate, 
9 A fine particle collector, for measuring the emitted mass fraction of fine drug 
particles, 
9 A pre-separator for retention of large particles, such as carrier crystals from dry 
powder inhalers, 
9 A vacuum system with flow control unit and flow measuring device. 
 
 In addition to these primary design parameters, some secondary specifications have 
been listed in Table 3.3. They extend the range of applications and make laser diffraction 
analysis of the aerosol cloud from inhalers with lda not only faster, but also more convenient 
and more accurate.  
 
Table 3.3. Some secondary design specifications for the inhaler adapter. 
9 Modular concept serving different applications for dpi’s, mdi’s and nebulisers 
9 Fast exchange and cleaning of adapter parts 
9 Minimal particle (droplet) accumulation onto inner walls (particularly the windows) 
9 Tilting construction for the measurement of nebulisers with sloping mouthpieces 
9 Front cylinders with different lengths to study the effects of droplet evaporation 
9 Low air flow resistance for a wide range of peak flow rates (PIF’s) and flow increase rates 
(FIR’s) 
9 Design prepared for combination with flow curve simulators 
9 Automatic recording of data, parameter settings and room temperature and humidity 
 
 
 The measuring chamber has been designed neither to interfere with the aerosol cloud 
nor with the laser beam. The concept is modular, so as to comply with the different demands 
for different types of inhalation systems, as well as to serve different types of experiments 
with these inhalers. In this chapter, only the adapter itself is described without reference to the 
vacuum control system or the principles of laser diffraction and additional equipment which 
may be helpful in inhaler testing. Particularly for the evaluation of dpi’s, a highly effective 
dry powder dispersion system is recommended with which primary drug particle size 
distributions can be obtained. They are used as reference for the size distributions measured in 
the aerosol clouds from these devices. Also, a suitable flow meter will be necessary for 
establishment of the specific air flow resistance of dpi’s to be tested, as flow control through 
the inhaler connected to the adapter is upon adjustment of the corresponding pressure drop 
across the device. 
 In its basic design for nebuliser testing (Fig. 3.1A, without Venturi meter), the adapter 
has a closed central housing for flow control through the inhalation device, a front cylinder 
with an exchangeable seal ring for differently shaped mouthpieces, and a conical rear cylinder 
for connection to the vacuum system, which includes a vacuum pump and flow control unit. 
The adapter has been developed specifically for Sympatec laser diffraction apparatus. This 
apparatus has two separate cabinets on a mechanical bench with a special support frame for 
different measuring systems in between these cabinets. The adapter is completely modular: 
parts can either be added to or removed from the central housing, so as to comply with the 
different requirements for different types of inhalation systems. The configuration shown in 
Fig. 3.1B is the most complete set-up for dpi testing with pre-separator and fine particle 
collector. The photograph shows the INHALER 2000TM, Sympatec GmbH, Goslar, Germany, 
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which is the marketed version of the prototype shown in Fig. 3.1A. Parts can also be modified 











































Fig. 3.1B. The marketed Sympatec INHALER 2000TM with pre-separator, fine particle collector for 
dpi testing and flow control unit (box on the right). 
 
 
 Different front cylinders with different lengths can be used for different types of 
nebulisers. All front cylinders have co-axial inner cylinders with smaller diameters to 











widening of the discharge cloud before it passes the laser beam. The inner cylinders are 




















Figure 3.2. Side view (top half) and cross section (bottom half) of the basic adapter concept, showing 
the inner cylinder. 
 
 
 All inner cylinders end directly in front of the laser beam. The central housing has two 
side cylinders (Fig. 3.1A). In the prototype, the side cylinders have no window. They can be 
elongated to make a close contact (against a seal ring at the end of each cylinder) with both 
cabinet parts of the laser diffraction apparatus, so as to constitute a closed housing. To 
eliminate uncontrolled leakage of false air into the housing, the fitting of the Fourier lens in 
the cabinet has been sealed as well. The more recent HELOS BF-MAGIC apparatus has a lens 
rotation unit which can not be sealed. Therefore, the side cylinder which opposes this rotation 
unit in the marketed (INHALER 2000TM) version of the inhaler adapter, has a removable 
window at its end. The side cylinders have adjustable vents (Fig. 3.1A: counter flow control 
ring) at their ends for a controlled inlet of false air. These air (counter) flows return fine 
particles which enter the side cylinders to the central housing and assist in keeping the 
windows clean. It has been found that the counter flows do not interfere with the flow control 
through the inhalation device. 
   Fig. 3.3 shows that the adapter can be tilted. This is to enable the connection of 
nebulisers with sloping mouthpieces to the adapter in a way that the nebulisation cup stays 
upright. The figure also shows a calibrated Venturi meter for flow measurement through the 
nebuliser. The Venturi meter can either be connected directly to the conical end of the 
adapter, or to a particle collector or washing bottle downstream of the adapter. When the 
Venturi meter is used, the tube connector for a differential pressure (dP) gauge on top of the 
central adapter housing is closed. In the most comprehensive configuration for dpi-testing 
(Figs. 3.1B and 3.4) the front cylinder is replaced by a pre-separator and a fine particle 
collector is connected to a modified conical rear end. The pre-separator is a single stage 
impactor, with a nozzle similar to the first stage of the Erweka multi stage liquid impinger 
(Fig. 3.4). The induction port to this pre-separator is a bent glass tube which has a coupling 
flange with exchangeable seal rings for the inhaler. The pre-separator is only used for dpi’s in 
Inner cylinder
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combination with adhesive mixtures. For pellet type of formulations, the standard front 
cylinder is applied. If the pre-separator is connected to the adapter, the pressure drop across 
the inhaler is measured at the position of the coupling flange and the tube connector on the 



















Figure 3.3. Side view of the tilted adapter concept for nebuliser testing with a Venturi meter connected 
to its conical rear end.  
 
 
   Without pre-separator, differential pressure measurement for dpi’s is at the top of the 
central housing. The pre-separator can easily be disconnected and disassembled for filter 
exchange (sampling) between experiments. Because powder de-agglomeration may be 
propagated inside the bent glass induction port, which is an undesired aspect, a vertical pre-
separator with straight inlet tube is in development. The fine particle collector is either a filter, 
similar to the fifth stage of the Erweka impactor, or a multi jet impinger with centrifugal 
action, as shown in Fig. 3.4. Collection of the fines allows the measurement of the released 
fine particle mass fraction. Similar to the pre-separator, the fine particle collector can easily 
be disconnected and disassembled for sampling. The vacuum system is not depicted. It 
consists of a rotary pump with a flow control unit, including a solenoid valve with timer and a 
flow controller for the adjustment of a constant flow rate over a preset inhalation time through 
the inhaler.  
   The low air flow resistance of the adapter, in combination with its relatively small 
volume (compared to most cascade impactors), practically imposes no limits on PIF and FIR 
through the inhalers. Measurement of the particle size distribution in the aerosol cloud from 
an inhaler can be completed within a few minutes; computing of the results is within seconds. 
A very special application is the performance of time-sliced measurements, which makes it 
possible to follow the size distribution of the cloud as function of the inhalation time or to 
assess the total emission time of the inhaler. All parts of the adapter are constructed of 
stainless steel. They can be earthed against unwanted electrostatic effects. During 

























Figure 3.4. Side view of the adapter configuration for dpi testing with horizontal pre-separator and 
multi-jet impinger type of fine particle collector. 
 
 
3. Materials and methods 
   For all experiments, the first generation marketed adapter (INHALER 2000TM) was 
used in combination with a HELOS BF/MAGIC, software version 4.1.2, and a 50 or 100 mm 
lens (Sympatec GmbH, Goslar Germany). All calculations were made on the basis of the 
Fraunhofer theory.  
 
3.1. Nebulisers 
   Nebuliser experiments were conducted without pre-separator and fine particle 
collector, but there was a washing bottle in between the adapter and the vacuum control unit 
to collect the fine droplets after laser diffraction sizing. Flow rates through the devices were 
measured with the calibrated Venturi meter; no counter flow through the side cylinders of the 
adapter was used. For all experiments, a 100 mm lens was used (measuring range: 0.9 – 175 
µm). Nebuliser cups were filled with amounts of liquid according to the prescriptions given 
by the manufacturers. Also recommended jet flows (pressures) were applied.  
   For the comparative evaluation study with 10% aqueous Tobramycin solution, a 
constant flow rate of 40 l/min was adjusted through the ten different nebulisers. Droplet size 
distribution measurements of 10 s each were performed 10s; 1.5; 3; 4; 5; 6; 9 and 12 min after 
the start of nebulisation, or stopped earlier in case of dry running of the nebulisation cup. 
Different front cylinders and different tilting angles were applied.  
   For the single experiment with the PortaNeb plus Sidestream (MedicAid, Romedic, 
Meersen, The Netherlands), the measuring time was 5 s. Measurement was repeated every 25 
s until the device, filled with demineralised water, ran dry after approximately 6 min, as could 
be monitored with the optical concentration of the aerosol cloud. 
 
3.2. Marketed dry powder inhaler 
   For experiments with a Pulmicort 200 Turbuhaler (AstraZeneca, Sweden), a fine 
particle collector of the impinger type was connected to the central adapter housing, but the 
pre-separator was not used, because this type of dpi contains spherical pellets with micronised 
Dry powder inhaler
Pre-separator
Fine paticle collector (fpc)
 96 
particles only. Comparative measurements (with a 100 mm lens) at two different flow rates 
were performed. Five inhalations at 30 l/min and three inhalations at 60 l/min were averaged 
and compared with the size distribution of the primary budesonide particles for the 
formulation from the Turbuhaler obtained with RODOS (Sympatec, Germany) dispersion at 4 
bar (mean of 3 series). Start and stop of the measurements was triggered on a detector signal 
of 0.2% on channel 30 (corresponding with fine particles < 0.9 µm in combination with a 100 
mm lens).  At 60 l/min, a minor (not recorded) counter flow through the side tubes was 
applied in order to keep the windows completely free of particles. To investigate the effect of 
this counter flow on the size distribution of the aerosol cloud, measurements were also 
conducted without counter flow, as well as with 45 and 90 l/min counter flow through the side 
cylinders (additional to the 60 l/min through the Turbuhaler). The counter flow was equally 
divided between both cylinders. Data given are the mean of two inhalation series per 
condition. 
 
3.3. Special test inhalers with carrier retention  
   Fig. 3.5 shows the basic concept of a test inhaler designed for formulation studies on 
adhesive mixtures. The concept has a disk shaped circulation chamber as de-agglomeration 



















Figure 3.5. Test inhaler with circulation chamber (air classifier) for dispersion of adhesive mixtures 
under the conditions of complete carrier retention. 
 
 
   A measured quantity of powder, comprising one single dose, enters the chamber 
through a tangential powder channel (powder feed channel). Bypass flow from a second 
channel, which also ends as a tangent to the cylindrical wall of the circulation chamber, 
contributes to a stable tangential flow pattern inside the chamber. During inhalation, the 
powder circulates by the action of the centrifugal force, unless particles have become so small 
(by de-agglomeration), that they can be entrained by the inspiratory air and be discharged 
through the mouthpiece tube. The circulation chamber has a relatively large cylindrical inner 
wall. The test inhaler itself acts as a pre-separator for large particles when it is used in 
combination with the inhaler adapter. In the range of flow rates between 30 and 60 l/min, only 





Therefore, experiments with this test inhaler concept have been performed without the pre-
separator shown in Figs. 3.1B and 3.4. The test inhaler has been used without a dose 
measuring principle. Small pre-weighed powder quantities were inserted into the channel for 
powder flow by spatula before the pre-set flow rate through the test inhaler was opened. Start 
(and stop) of the particle size distribution measurement was initiated upon reaching a detector 
signal of 0.2% (or 0.5%, dependent on the application) on channel 30. All data given are the 
mean of 5 or 6 inhalations. 
   In one application, the test inhaler has been used for the development of colistin 
(sulfate) dry powder formulations which were not adhesive mixtures. The formulations 
(physical mixtures) contained 83.3% colistin sulfate, in a size distribution between 
approximately 0.1 and 80 µm, and 16.7% crystalline alpha lactose monohydrate, in a size 
fraction of 106-150 µm obtained by air jet sieving. The relatively large lactose crystals in this 
formulation act as sweeper crystals; they wipe adhering fine drug particles off cylindrical 
walls of the classifier chamber during inhalation. The size distributions of the colistin aerosol 
clouds from the test inhaler at 60 l/min for six doses of 12 mg have been analysed (with a 100 
mm lens) while using the adapter in combination with a washing bottle. The data have been 
compared with (a) the primary size distribution of the colistin sulfate obtained from RODOS 
dispersion at 4 bar and (b) the size distribution of the cloud from the Pharmachemie 
Cyclohaler (Pharbita, The Netherlands) at the same flow rate of 60 l/min. For the test with the 
Cyclohaler, hard gelatin capsules (no. 3) were filled with 10 mg of the pure drug and the 
capsules were sealed before use to prevent sliding of the cap over the body during perforation 
inside the inhaler. There was no lactose in the formulation for the Cyclohaler, because (a) no 
sweeper function is required for this inhaler device and (b) larger particles were found to 
block the discharge holes in the capsule. 
   In another application of the test inhaler, a mixture of two different marketed lactose 
brands was used as carrier for an adhesive mixture with 1% budesonide (X50 = 1.03 and X99 =  
3.95 µm for the drug obtained with RODOS dispersion at 5 bar). The lactose mixture 
contained 85% (w/w) of Pharmatose 325M and 15% Pharmatose 150M (both: DMV 
International, The Netherlands). Both qualities of lactose are currently used as carrier for 
inhalation and were selected to obtain a carrier mixture with a substantial amount of fine 
particles in the size range of the drug (5.0% < 3.6 µm from RODOS dispersion at 5 bar). 
Mixing time of the carrier blend with budesonide was 10 min in a Turbula T2C tumbler mixer 
(W.A. Bachofen, Basel, Switzerland) at 90 rpm (batch size 25 gram in a 160 ml stainless steel 
container). Five inhalations with 25 mg of the carrier blend from the test inhaler were 
performed at 30, 40 and 50 l/min respectively, as reference measurements. The mixture with 
1% budesonide was then tested under the same conditions. The differences between (mean) 
reference measurements and corresponding (mean) drug measurements (50 mm lens) were 
calculated and expressed as size distribution curves for the drug. For this application, a minor 
counter flow through the side tubes was applied. 
 
 
4. Results and discussion 
   Fig. 3.6 presents the results from comparative nebuliser testing with a 10% aqueous 
tobramycin solution. Only minor fluctuations in time for the droplet size distribution per 
nebuliser were observed and differences between three duplicate series with the same device 
were negligible. Therefore, all data per nebuliser have been averaged, excluding the data 
obtained during dry running.  
   The volume median diameter (X50-value) of the aerosol clouds from different devices 
varies between 1.25 and 3.25 µm at the inspiratory flow rate of 40 l/min. In general, the span 
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of the size distribution (X10 to X90) increases with the median droplet size from 0.63-2.31 µm 


















Figure 3.6. Droplet size distribution, expressed as X10, X50 and X90-values, from marketed jet and 
ultrasonic nebulisers MicroCirrus (MCR), Freeway Lite with Sidestream (FLS), PortaNeb with 
Sidestream (PNS), PortaNeb with Ventstream (PNV), Pari Boy with LC Plus (PLC), Medix Sonic 
2000 (MS), Medasonic System Jr (MSJ), DeVilbiss Pulmo-Aide with Hudson T Updraft (DVH), 
Wisto Senior (WSR) and DeVilbiss Pulmo-Aide with Sidestream (DVS), for a 10% aqueous 




 Fig. 3.7 shows for the PortaNeb with Sidestream that the droplet size distribution, 
expressed as X10, X50 and X90-values, is very constant during nebulisation, until the device 
begins to run dry, which can be observed from a sudden decrease in the optical concentration 
of the aerosol cloud (Fig. 3.7). Shortly before the nebulisation cup is empty, large droplets 
may be discharged as a consequence of spatter (discontinuous flow from the two fluid nozzle 















Figure 3.7. Droplet size distribution (left), expressed as X10, X50 and X90-values, as function of the 
nebulisation time from the PortaNeb with Sidestream for demineralised water. Corresponding optical 






























































































 In Fig. 3.8, the size distributions of the aerosol cloud from the Pulmicort 200 
Turbuhaler for two different flow rates are presented, in comparison with the size distribution 

















Figure 3.8. Size distribution of the aerosol cloud from the Pulmicort 200 Turbuhaler as function of the 
flow rate (30 and 60 l/min). Bars indicate the spread (maximal and minimal values) between the 
individual inhalations. The curve marked with asterisks represents the primary particle size 
distribution of the drug obtained from RODOS dispersion at 4 bar. 
 
 
 The curves show that the de-agglomeration efficiency of the Turbuhaler strongly 
improves with increasing flow rate. At 30 l/min, the volume median diameter (vmd) is still 
5.52 µm (spread is 5.15 to 5.90 µm), but at 60 l/min X50 decreases to 2.53 µm (spread: 2.16 to 
2.76 µm; n=6). The difference with the vmd of the primary drug particles (1.61 µm with a 
spread from 1.58 to 1.62 µm) proves that mainly small agglomerates (instead of primary drug 
particles) are released from the inhaler and that the average number of entities per 
agglomerate decreases with increasing flow rate. The value of lda for dpi testing is therefore, 
to assess the de-agglomeration efficiency of the device as function of flow rate, inhaler design 
or type of powder formulation. This can serve development and optimisation of devices and 
formulations, as well as quality control. The data in Fig. 3.8 have been obtained with a minor 
counter flow through the side channels (approximately 20 l/min, which is additional to the 
flow rate through the inhaler). A counter flow rate of this order of magnitude has a negligible 
effect on the size distribution in the aerosol from the inhaler. With an additional counter flow 
of 40 l/min the X50-value becomes 2.47 µm (n=6), and first at 90 l/min additional flow 
through the side cylinders the X50-value decreases further to 2.27 µm. This may seem 
significantly lower, but the value is still within the spread range indicated above. A counter 
flow rate which is higher than the flow rate through the inhaler is not necessary however. 
   Fig. 3.9 shows the mean size distribution curves of the colistin aerosols from the 
special test inhaler (with carrier retention) and the Cyclohaler. The spread of the individual 
inhalations (minimal and maximal values) is indicated with bars. The volume median 
diameter of the aerosol cloud from the Cyclohaler (24.33 µm) is much larger than that of the 
primary colistin particles (2.14 µm) which are quite cohesive and difficult to disintegrate. In 
contrast, the X50 of the cloud from the test inhaler is only 2.24 µm with a spread between 2.14 
and 2.32 micron. The X100-value for the aerosol cloud from the test inhaler is approximately 
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test inhaler at 60 l/min. This is much lower than the X100-value for the used colistin fraction 

















Figure 3.9. Size distribution curves of colistin sulfate at 60 l/min from a special test inhaler with 
carrier retention and the marketed Cyclohaler (capsule dpi) for formulations with and without 16.7% 
of a lactose fraction 106-150 µm respectively. Bars indicate the spread (maximal and minimal values) 
between the individual inhalations. The curve marked with asterisks is for the primary drug particle 
size distribution from RODOS dispersion (4 bar). 
 
 
 The results from the carrier mixture with 1% budesonide are depicted in Fig. 3.10. In 
spite of the emission of all lactose carrier particles that are smaller than the cut-off diameter of 
the test inhaler, and even a few particles larger than this cut-off value, highly indicative size 

















Figure 3.10. Computed mean particle size distribution curves for budesonide from an adhesive mixture 
with 85% (w/w) Pharmatose 325M and 15% Pharmatose 150M, using the special test inhaler with 
carrier retention (as pre separator) at 30, 40 and 50 l/min. The curve marked with asterisks is for the 
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 The computed mean vmd of the released drug fraction decreases from 5.75 µm at 30 
l/min to 1.82 µm at 40 l/min, and further to 1.53 µm at 50 l/min. In comparison, X50 for the 
drug from RODOS dispersion (primary particles) is 1.03 µm. The results show that powder 
de-agglomeration with the test inhaler for this budesonide formulation is nearly complete at 
40 and 50 l/min. But at 30 l/min, small drug agglomerates are released. This is confirmed by 
cascade impactor data obtained with the same formulation and test inhaler. The third stage of 
the impactor used for the experiments, has a theoretical cut-off diameter of 6.74 µm for 
budesonide at 30 l/min. At this flow rate, 27.2% of the real dose is deposited on stage four. 
This equals 58.2 mass percent of the emitted dose (the carrier particles with residual drug are 
retained by the test inhaler). In comparison, from the cumulative distribution curve of the 
aerosol cloud obtained with laser diffraction analysis, a volume percent of 56.3 for particles 
smaller than 6.47 µm can be derived.  The good agreement in results proves that the 
subtraction method (correction of the drug measurement for the reference measurement with 
pure carrier) can be applied successfully for adhesive mixtures. Even if they contain amounts 
of active substance that are lower than the amounts of fine lactose particles in the carrier. A 
prerequisite is that the larger carrier particles are retained. This can not only be achieved by 
the special test inhaler used for the experiments, but also with the pre-separator that has been 
developed for the inhaler adapter. 
   Particular relevant for inhaler testing is that the (cumulative) size distribution curves 
from lda comprise fourteen different size classes for the fine particle fraction (< 5.25 µm for 
the 50 mm lens). The significance of this high number of size classes for comparative 
evaluation is much greater than that of measuring geometric, rather than aerodynamic 
diameters, with laser diffraction. Especially, when also the fine particle mass fraction, to 
which this size distribution refers, from analysis of the fine particle collector is known. This 
enables dividing of the fine particle mass fraction into the size classes that are relevant to 
deposition in the human respiratory tract (assuming that particle density is independent of 
particle size and thus, that the volume distribution as function of the diameter equals the mass 
distribution). Dividing would have to be in size classes that are able to enter different regions 
of the respiratory tract and exhibit different deposition mechanisms in these regions. This can 
never be achieved with most currently used (cascade) impactors, simply because they have 
insufficient size classes (one to three) within the fine particle fraction (generally the fraction  




   The presented selection of early data obtained with the newly developed inhaler 
adapter (INHALER 2000TM) shows that laser diffraction can be a valuable technique for 
comparative evaluation of nebulisers and dry powder inhalers. The adapter facilitates 
complete control of relevant conditions, such as the inspiratory flow parameters, whereas the 
measuring principle operates widely independent of these conditions. This, in contrast with 
cascade impactor analysis. In addition, the adjustable ranges of the important inspiratory flow 
parameters, e.g. peak inspiratory flow rate (PIF), flow increase rate (FIR) and inhalation time, 
are much wider. Furthermore, time-sliced measurements make it possible to follow the size 
distribution of the emitted aerosol particles as function of the inhalation time or to measure 
total emission time of an aerosol generator. Special (additional) parts, including the discussed 
pre-separator and fine particle collector, expand its application towards testing of dpi’s, even 
when these contain adhesive mixtures with relatively coarse carrier crystals. Mass fractions of 
the emitted fine particle dose can be measured, for which a much greater number of classes is 
available than can be obtained with currently used cascade impactors. For nebulisers and 
metered dose inhalers, expression of the measured laser diffraction diameters into 
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aerodynamic diameters according to the definition is mostly quite well possible, if necessary. 
Considering the many disadvantages of cascade impactor analysis, it may be expected that 
laser diffraction analysis will become a widely accepted alternative for testing of these types 
of aerosol generators. For dpi’s, accurate data interpretation requires somewhat more insight 
and understanding of the working principle of both the type of inhalation system and the 
principle of laser diffraction. But then, lda can also be a valuable tool for development and 
quality control of dpi’s. Not only because laser diffraction is highly reproducible and 
sensitive, as a consequence of which the results from single inhalations can be studied. But 
more particularly because the technique is very fast, compared with cascade impactor 
analysis. The adapter presented and discussed in this paper is only a first generation device. 
Further developments and improvements will follow, especially regarding coarse particle pre-
separation, fine particle collection and flow curve generation through the adapter. In addition, 
laser diffraction and adapter evaluation programs will be started and ‘user-specific systems’ 
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